Sensus Healthcare, Inc. (NASDAQ:SRTS) Anticipated to Put up Earnings of $0.18 Per Share


Equities research analysts expect Sensus Healthcare, Inc. (NASDAQ:SRTSGet Rating) to announce per share of $0.18 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Sensus Healthcare’s earnings, with the lowest EPS estimate coming in at $0.15 and the highest estimate coming in at $0.21. Sensus Healthcare posted of ($0.02) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 1,000%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Sensus Healthcare will report full-year earnings of $1.53 per share for the current financial year, with EPS estimates ranging from $1.32 to $1.74. For the next year, analysts anticipate that the company will report earnings of $0.93 per share, with EPS estimates ranging from $0.55 to $1.30. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that provide coverage for Sensus Healthcare.

Sensus Healthcare (NASDAQ:SRTSGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.06 by $0.91. Sensus Healthcare had a return on equity of 38.23% and a net margin of 62.07%. During the same quarter last year, the firm earned ($0.07) earnings per share.

SRTS has been the topic of a number of research analyst reports. TheStreet raised Sensus Healthcare from a “c” rating to a “b-” rating in a report on Friday, February 11th. Zacks Investment Research raised Sensus Healthcare from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Thursday. HC Wainwright raised their target price on Sensus Healthcare from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, March 3rd. Finally, Maxim Group restated a “buy” rating and issued a $14.00 target price on shares of Sensus Healthcare in a research report on Friday, May 6th.

In other Sensus Healthcare news, CFO Javier Rampolla sold 9,000 shares of the business’s stock in a transaction dated Friday, March 4th. The stock was sold at an average price of $9.42, for a total value of $84,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Nicolas Soro sold 10,000 shares of the business’s stock in a transaction dated Wednesday, March 9th. The stock was sold at an average price of $10.20, for a total value of $102,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,056 shares of company stock valued at $1,227,218. 24.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dorsey Wright & Associates acquired a new position in shares of Sensus Healthcare in the 1st quarter worth approximately $54,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Sensus Healthcare by 83.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. Now owns 5,500 shares of the company’s stock worth $40,000 after buying an additional 2,500 shares in the last quarter. HCR Wealth Advisors acquired a new position in Sensus Healthcare during the 4th quarter worth $72,000. AE Wealth Management LLC acquired a new position in Sensus Healthcare during the 1st quarter worth $192,000. Finally, Goldman Sachs Group Inc. acquired a new position in Sensus Healthcare during the 4th quarter worth $141,000. 20.49% of the stock is currently owned by institutional investors.

SRTS stock Opened at $8.97 on Thursday. Sensus Healthcare has a 1 year low of $3.08 and a 1 year high of $11.96. The firm has a market cap of $149.62 million, a P/E ratio of 7.01 and a beta of 0.52. The stock has a 50-day simple moving average of $9.22 and a 200-day simple moving average of $8.06.

About Sensus Healthcare (Get Rating)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids ; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

See Also

Get a free copy of the Zacks research report on Sensus Healthcare (SRTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for Sensus Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sensus Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment